Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.38 |
| ▸ | KDM4A | O75164 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.38 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL13505613 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL7026852 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL4263083 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL419437 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL41708 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL424598 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL4261279 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL5269783 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL2286708 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL15008846 | 0.97 | TP53 (0.65) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637077-B2 | Sustained-release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-28 | — | — | US | disclosed |
| EP-2515878-B1 | SUSTAINED-RELEASE FORMULATION | TAKEDA PHARMACEUTICAL (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-20120302508-A1 | SUSTAINED-RELEASE FORMULATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2515878-A2 | SUSTAINED-RELEASE FORMULATION | Takeda Pharmaceutical Company Limited (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20090142399-A1 | DISPERSANT AGENT FOR SUSTAINED-RELEASE PREPARATIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-2062593-A2 | Method for producing preparation containing bioactive peptide | Takeda Pharmaceutical Company Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-20070038289-A1 | Stent to be placed in vivo | KANEKA CORPORATION (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20060241045-A1 | Method for producing preparation containing bioactive substance | OHMACHI YOSHIHIRO | 2006-10-26 | — | — | US | disclosed |
| US-7090869-B2 | Method for producing preparation containing bioactive substance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| EP-1652550-A1 | STENT TO BE PLACED IN VIVO | KANEKA CORPORATION (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20060088595-A1 | Dispersant for sustained release preparations | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1595549-A1 | DISPERSANT FOR SUSTAINED RELEASE PREPARATIONS | Takeda Pharmaceutical Company Limited (JP) | 2005-11-16 | — | — | EP | disclosed |
| US-20040057996-A1 | Sustained-release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| US-20040018240-A1 | Method for producing preparation containing bioactive substance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1356809-A1 | SUSTAINED RELEASE PREPARATIONS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1346722-A1 | METHOD FOR PRODUCING PREPARATION CONTAINING BIOACTIVE SUBSTANCE | Takeda Chemical Industries, Ltd. (JP) | 2003-09-24 | — | — | EP | disclosed |
| EP-0946169-A2 | METHOD OF PRODUCING A SUSTAINED-RELEASE PREPARATION | Takeda Chemical Industries, Ltd. (JP) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027980-A2 | METHOD OF PRODUCING A SUSTAINED-RELEASE PREPARATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241045-A1 | Method for producing preparation containing bioactive substance | BMP2, BMP4, BMP1 | TP53 2472/4885OR51E2 811/4885CYP1A2 1841/4885 |
| US-20040018240-A1 | Method for producing preparation containing bioactive substance | BMP2, BMP4, BMP1 | TP53 2472/4885OR51E2 811/4885CYP1A2 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.